Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04394624
Title Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04) (CARMEN-LC04)
Acronym CARMEN-LC04
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sanofi
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ESP

Facility Status City State Zip Country Details
Henry Ford Hospital Site Number : 8400005 Detroit Michigan 48202 United States Details
Roswell Park Cancer Institute Site Number : 8400003 Buffalo New York 14263 United States Details
McClinton Cancer Center Site Number : 8400002 Waco Texas 76712 United States Details
Investigational Site Number : 1000001 Plovdiv 4004 Bulgaria Details
Investigational Site Number : 2030001 Ostrava - Vitkovice 703 84 Czechia Details
Investigational Site Number : 2030002 Praha 2 12808 Czechia Details
Investigational Site Number : 4100001 Seoul Seoul-teukbyeolsi 03080 Korea, Republic of Details
Investigational Site Number : 4100002 Seoul Seoul-teukbyeolsi 03722 Korea, Republic of Details
Investigational Site Number : 6200001 Porto 4200-162 Portugal Details
Investigational Site Number : 7240001 Barcelona / Sabadell Catalunya [Cataluña] 08208 Spain Details
Investigational Site Number : 7240005 Madrid Madrid, Comunidad De 28046 Spain Details
Investigational Site Number : 7240004 Madrid 28040 Spain Details
Investigational Site Number : 7240003 Zaragoza 50009 Spain Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field